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A B S T R A C T
Nanoparticles and molecular chromophores with strong optical absorption in the near-infrared spectral
range can be used as contrast agents for optoacoustic (photoacoustic) imaging, thereby signiﬁcantly
enhancing sensitivity and enabling new applications of this novel and rapidly growing biomedical
imaging technology.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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new biomedical imaging technology that generates images by
illuminating tissues with laser pulses and detecting resulting
ultrasound waves [1,2]. OAT takes advantage of spectroscopic
approach to molecular imaging, and delivers high-resolution
images in the depth of tissue. Resolution of the optoacoustic
imaging is scalable, so that biomedical systems from cellular
organelles to large organs can be visualized and, more importantly,
characterized based on their optical absorption coefﬁcient [3]. OAT
was shown useful in both, preclinical research using small animal
models and clinical applications [4–10]. Applications in the ﬁeld of
molecular imaging offer abundant opportunities for the develop-
ment of highly speciﬁc and effective contrast agents for biomedical
optoacoustic imaging [11–13]. Advances in the area of plasmonic
nanotechnology opened such opportunities for development of
nanoparticle based contrast agents with exceptionally strong
absorption in the near-infrared (NIR) spectral range for preclinical
applications of optical and optoacoustic imaging [14]. The use of
plasmon resonance absorption in metal nanoparticles has been
invoked for a diverse range of in vivo and in vitro applications
including imaging and monitoring of tissue, sensing of molecules,
cells and harmful microorganisms [15–17] as well as selective
optothermal therapy [18,19]. The very recent efforts are being
made in the direction of nontoxic biodegradable contrast agents
(such as nanoparticles made of biopolymers, melanin and
indocyanine green) potentially applicable in clinical optoacoustic
imaging [20–22]. It is noteworthy that molecular contrast agents
being developed for optical imaging modalities (such as ﬂuores-
cence imaging) are directly applicable to the optoacoustic imaging
[23,24]. Furthermore, optoacoustic contrast agents can be com-
bined with ultrasonic contrast agents for dual modality imaging
[25–27]. One area of particular relevance to optoacoustic imaging
is the enhancement of malignant tumor contrast relative to
background normal tissue [28,29]. Once cancerous lesion ishttp://dx.doi.org/10.1016/j.pacs.2015.01.002
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4.0/).detected, it is only logical to use lasers and/or ultrasound for
minimally invasive therapy of cancer [30–32]. Optoacoustic
imaging systems can be used for molecular imaging and
monitoring physiological processes in preclinical research applica-
tions using mouse models of cardiovascular and other diseases
[33]. In addition, in combination with reporter genes, these
systems offer promise for imaging genetic processes, monitoring
the delivery of speciﬁc genes to target cells and visualizing the
kinetics of therapeutic gene expression [34,35]. In order to
increase efﬁciency and speciﬁcity of contrast agents and probes,
they can be made smart and capable of controlled accumulation in
the target cells [36] or activatable with external electromagnetic
energy [37,38]. Recognizing the potential breakthroughs in
optoacoustic imaging that can be achieved using variety of
technological advances made in the past decade in the ﬁeld
of optical, optoacoustic and ultrasonic contrast agents, we invited
the biomedical optics community and biomedical ultrasound
community to join the bionanotechnology community and the
optoacoustic imaging and sensing community by contributing to
this special issue of Photoacoustics dedicated to contrast agents
and their biomedical applications.
Alexander Oraevsky
Guest Editor
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